Neuroscience 295 (2015) 187–197

EVIDENCE FOR A ROLE FOR α6* nAChRs IN L-DOPA-INDUCED DYSKINESIAS USING PARKINSONIAN α6* nAChR GAIN-OF-FUNCTION MICE

T. BORDIA,[a] M. MCGREGOR,[a] J. M. MCINTOSH,[b,c] R. M. DRENAN[d] AND M. QUIK[a]*

[a] *Center for Health Sciences, SRI International, Menlo Park, CA 94025, USA*

[b] *George E. Wahlen Veterans Affairs Medical Center, Department of Psychiatry, University of Utah, Salt Lake City, UT 84148, USA*

[c] *Department of Biology, University of Utah, Salt Lake City, UT 84148, USA*

[d] *Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN 47907, USA*

Abstract—L-Dopa-induced dyskinesias (LIDs) are a serious side effect of dopamine replacement therapy for Parkinson's disease. The mechanisms that underlie LIDs are currently unclear. However, preclinical studies indicate that nicotinic acetylcholine receptors (nAChRs) play a role, suggesting that drugs targeting these receptors may be of therapeutic benefit. To further understand the involvement of α6β2* nAChRs in LIDs, we used gain-of-function α6* nAChR (α6L9S) mice that exhibit a 20-fold enhanced sensitivity to nAChR agonists. Wildtype (WT) and α6L9S mice were lesioned by unilateral injection of 6-hydroxydopamine (6-OHDA, 3 μg/ml) into the medial forebrain bundle. Three to 4 wk later, they were administered L-dopa (3 mg/kg) plus benserazide (15 mg/kg) until stably dyskinetic. L-dopa-induced abnormal involuntary movements (AIMs) were similar in α6L9S and WT mice. WT mice were then given nicotine in the drinking water in gradually increasing doses to a final 300 μg/ml, which resulted in a 40% decline AIMs. By contrast, there was no decrease in AIMs in α6L9S mice at a maximally tolerated nicotine dose of 20 μg/ml. However, the nAChR antagonist mecamylamine (1 mg/kg ip 30 min before L-dopa) reduced L-dopa-induced AIMs in both α6L9S and WT mice. Thus, both a nAChR agonist and antagonist decreased AIMs in WT mice, but only the antagonist was effective in α6L9S mice. Since nicotine appears to reduce LIDs via desensitization, hypersensitive α6β2* nAChRs may desensitize less readily. The present data show that α6β2* nAChRs are key regulators of LIDs, and may be useful therapeutic targets for their management in Parkinson's disease.

Key words: dyskinesia, L-dopa, nicotine, 6-hydroxydopamine, Parkinson's disease.

INTRODUCTION

Long-term L-dopa use is complicated by the emergence of abnormal involuntary movements (AIMs) or dyskinesias, for which there are currently few treatments (Huot et al., 2011; Connolly and Lang, 2014). There is thus a critical unmet need for therapies to reduce L-dopa-induced dyskinesias (LIDs). Preclinical studies suggest a compelling role for the nicotinic cholinergic system (Quik et al., 2014). Nicotine administration alleviated LIDs up to 60% in a variety of parkinsonian animal models, suggesting it may represent a useful treatment option (Quik et al., 2007; Bordia et al., 2008; Huang et al., 2011a).

Nicotine generally exerts its effects in the brain by acting at nicotinic acetylcholine receptors (nAChRs), of which there are several subtypes. The primary subtypes in the striatum, a region prominently affected in Parkinson's disease and linked to LIDs, are the α4β2*, α6β2* and α7 nAChRs. The asterisk indicates the possible presence of other subunits in the receptor complex (Millar and Gotti, 2009; Quik and Wonnacott, 2011). Two approaches have proved useful in delineating the nAChRs that mediate the nicotine-induced decline in LIDs. One of these involves the use of drugs targeting select nAChRs. Work with α7 nAChR agonists showed that administration of ABT-107 or AQW051 to monkeys led to ~60% decline in LIDs (Di Paolo et al., 2014; Zhang et al., 2014b). β2* nAChR agonists, which act at both α4β2* and α6β2* subtypes, also significantly reduced LIDs in parkinsonian rats and monkeys. Varenicline, ABT-089, ABT-894, TC-8831, as well as other TC-agonists, attenuated LIDs by 30–60% (Huang et al., 2011b; Johnston et al., 2013; Quik et al., 2013a; Zhang et al., 2013, 2014a). Interestingly, the general nAChR antagonist mecamylamine also reduced LIDs to a similar extent as nicotine and nAChR agonists (Bordia et al., 2010). This latter finding led to the suggestion that agonists may reduce LIDs by a nAChR desensitization block, a mechanism through which agonists also

*Corresponding author. Tel: +1-650-859-6112; fax: +1-650-859-5099.
E-mail address: maryka.quik@sri.com (M. Quik).

Abbreviations: α-CtxMII, α-conotoxinMII; *, denotes the possible presence of other subunits in the receptor complex; ^{125}I-RTI-121, ^{125}I-3β-(4-iodophenyl)tropane-2β-carboxylic acid isopropyl ester; 6-OHDA, 6-hydroxydopamine; AIMs, abnormal involuntary movements; BSA, bovine serum albumin; EDTA, ethylenediaminetetraacetic acid; EGTA, ethylene glycol tetraacetic acid; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; LIDs, L-dopa-induced dyskinesias; NAChRs, nicotinic acetylcholine receptors; WT, wildtype.

http://dx.doi.org/10.1016/j.neuroscience.2015.03.040
0306-4522/

modulate other behaviors (Picciotto et al., 2008; Buccafusco et al., 2009). The idea that LIDs are reduced because of a nAChR blockade is also consistent with a recent study which showed that ablation of striatal cholinergic interneurons, which results in a loss of acetylcholine, markedly reduced LIDs (Won et al., 2014).

Studies with genetically modified mice lend further support to the idea that multiple nAChRs are involved in the regulation of LIDs. Deletion of the α7 nAChR led to an increase in baseline LIDs, although it did not affect the antidyskinetic effect of nicotine (Quik et al., 2013b). By contrast, mice lacking β2* nAChRs, that is, both the α4β2* and α6β2* subtypes, exhibited a 50% decline in baseline LIDs. In addition, nicotine treatment no longer reduced LIDs in β2 null mutant mice. Selective subunit deletion of only the α4 nAChR subunit resulted in a loss of the antidyskinetic effect of nicotine with no change in baseline LIDs. By contrast, deletion of only the α6 nAChR subunit led to a decline in baseline LIDs together with a loss of the antidyskinetic effect of nicotine. These latter findings suggest an important role for α6β2* nAChRs in LIDs (Quik et al., 2012).

The objective of the current study was to use gain-of-function α6L9S mice to further explore the role of α6β2* nAChRs in LIDs. These mice express an α6* nAChR subunit in which the Leu 9′ residue in the M2 transmembrane domain is mutated to a Ser (Drenan et al., 2008). This mutation results in an α6β2* nAChR channel hypersensitive to endogenous acetylcholine or nAChR agonists, with a consequent increase in dopaminergic function (Drenan et al., 2008, 2010; Wang et al., 2014). In addition, transgenic mice expressing α6L9S nAChRs exhibit a variety of enhanced ambulatory behaviors, including walking, turning and rearing (Drenan et al., 2010). The present data using such transgenic mice further support a role for α6β2* nAChRs in LIDs.

EXPERIMENTAL PROCEDURES

Animals and nigrostriatal lesioning

Gain-of-function α6L9S mice and their wildtype (WT) littermates were bred, raised and genotyped at Purdue University, as described (Drenan et al., 2008). Adult male mice (20–35 g) were then shipped to SRI for lesioning, behavioral and biochemical studies. Upon arrival, mice were group housed in a room with controlled temperature and humidity, and a 12-h light/dark cycle. The mice had free access to food and water. After 1 wk of acclimation, the mice were lesioned by unilateral intracranial injection of 6-hydroxydopamine (6-OHDA) (Sigma–Aldrich Co., St. Louis, MO, USA) into the right medial forebrain bundle, as described (Lundblad et al., 2004, 2005; Huang et al., 2011a; Quik et al., 2012, 2013b). 6-OHDA (3 μg free base/μl in 0.9% saline containing 0.02% ascorbic acid) was stereotaxically injected under isofluorane anesthesia at the following site: anteroposterior, −1.2; lateral, −1.2; ventral, 4.75, relative to the bregma. The cannula was slowly lowered into the brain, with 6-OHDA delivered over a 2-min period. The cannula was maintained at the target site for an additional 2 min, followed by a 2-min removal period. Buprenorphine (0.3 mg/kg) was injected subcutaneously for post-operative pain management and a 0.5-ml aliquot of physiological saline to minimize dehydration. Following surgery, a 20% sucrose solution containing ground food pellets was placed at the bottom of the cage to assist feeding for 1–2 wk, as necessary.

All procedures were approved by the Institutional Animal Care and Use Committee in accordance with the NIH. All efforts were made to minimize animal suffering and to reduce the number of animals used.

Behavioral measurements

Three weeks after 6-OHDA lesioning, mice were assessed for nigrostriatal damage using the forelimb use asymmetry test (cylinder test) (Fig. 1). Mice were placed singly in a transparent cylinder and rated for 3 min for exploratory activity by a blinded rater (Huang et al., 2011a; Quik et al., 2012, 2013b). Contacts with the container wall using the impaired forelimb (contralateral to the lesion) were expressed as % of total forelimb contacts.

Mice were then administered L-dopa (3 mg/kg) plus benserazide (15 mg/kg) (both from Sigma–Aldrich Co., St. Louis, MO, USA) subcutaneously once daily 3 d per wk (Fig. 1), as described (Huang et al., 2011a; Quik et al., 2012, 2013b). Two weeks later, they were assessed for L-dopa-induced AIMs. Briefly, mice were injected with L-dopa and placed in separate clear containers. Ten minutes after the injection they were scored individually for 1 min every 15 min over a 2-h period by a blinded rater. Each AIM subtype (oral, forelimb, and axial) was scored on a frequency scale ranging from 0 to 4 (0 = no AIMs; 1 = occasional AIMs displayed <50% of the observation time; 2 = sustained AIMs for >50% of the observation time; 3 = continuous AIMs; 4 = continuous AIMs not interruptible by external stimuli). Each of the AIM subtypes was also scored for amplitude designated as A or B, with "A" representing oral AIMs without tongue protrusion, forelimb AIMs without shoulder involvement, and axial AIMs with body twisting <60°. "B" represented oral AIMs with tongue protrusion, forelimb AIMs with shoulder involvement or axial AIMs with body twisting >60°. The total score per mouse at any time point was calculated as follows; 1A = 1, 1B = 2, 2A = 2, 2B = 4, 3A = 4, 3B = 6, 4A = 6, 4B = 8, with a score for any one component (axial, oral or forelimb) ranging from 0 to 8. Therefore, the maximum possible score for each mouse was 192 (max score per session = 24, with eight sessions over the 2-h period).

Drug treatments

After 3 wk of L-dopa treatment when dyskinesias are stably expressed, α6L9S and WT mice were acclimated to 2% saccharin drinking solution for 2 d. Saccharin was necessary to mask the bitter of taste of nicotine (Fig. 1). The two genotypes were then divided into two groups each, with one receiving drinking water with only saccharin and the other saccharin-containing nicotine. The mean total dyskinesia scores were similar in all groups. For the WT mice, nicotine treatment was started at a dose of 25 μg/ml for 2 d, 50 μg/ml for 2 d, 100 μg/ml for 3 d, 200 μg/ml for 3 d and then 300 μg/ml, at



Fig. 1. Treatment schedule. α6L9S mice and their WT littermates were unilaterally lesioned with 6-OHDA. The forelimb asymmetry test was then done to evaluate motor deficits. The mice were subsequently rendered dyskinetic by once daily injection of L-dopa plus benserazide for 3 wk. They were rated for L-dopa-induced AIMs throughout the study. At wk 9 (gray box) all mice were acclimated for 2–3 d to 2% saccharin solution after which they were either continued on saccharin or given nicotine as indicated in the timeline. The white box represents the number of wk of nicotine treatment. L-Dopa and nicotine treatments were continued until the time of death.

dose at which the WT mice were maintained, as previously described (Huang et al., 2011a; Quik et al., 2012, 2013b). Previous work by others has shown that such a dosing regimen yields brain nicotine levels of approximately 1 μM, with smoking levels about 0.3 μM (Gaddnas et al., 2001; Matta et al., 2007).

The α6L9S mice were also given 25 μg/ml nicotine in the drinking water for 2 d, 50 μg/ml for 3 d, followed by 100 μg/ml. However, five of the 20 α6L9S mice died at this dose after 7 d of treatment. The nicotine was therefore decreased to 75 μg/ml for 7 days with three more deaths, followed by a reduction to 50 μg/ml with two deaths, followed by a reduction to 25 μg/ml with two more deaths, with only one mouse death at 20 μg/ml. The enhanced sensitivity of α6L9S to nicotine is consistent with previous behavioral and electrophysiological studies which demonstrated a ~20 times greater sensitivity to nicotine (Drenan et al., 2008).

The mouse weights were not affected by nicotine treatment, although the weights of the α6L9S mice were somewhat lower than the WT littermates. Values (g) at wk 10 (white box in timeline) were as follows: WT saccharin 43 ± 2 (n = 10) and WT nicotine 37 ± 2 (n = 10); α6L9S saccharin 34 ± 1 (n = 10) and α6L9S nicotine 31 ± 1 (n = 7).

Tissue preparation

Mice were killed by cervical dislocation 45 min after L-dopa administration. The brains were quickly removed and quick frozen in isopentane on dry ice and stored at −80 °C. When required, 8-μm sections were cut at −15 °C in a cryostat (Leica Microsystems Inc., Deerfield, IL, USA), thaw mounted onto poly-L-lysine-coated slides, dried, and stored at −80 °C.

Binding studies

Striatal dopamine transporter binding was performed using ^{125}I-3β-(4-iodophenyl)tropane-2β-carboxylic acid isopropyl ester (^{125}I-RTI-121, specific activity 2200 Ci/mmol; PerkinElmer Life and Analytical Sciences, Waltham, MA, USA) as described (Quik et al., 2003). This technique was used because it provides a quantitative assessment of dopamine transporter levels (Quik et al., 2003). To measure transporter levels, the sections were first pre-incubated at room temperature for two 15-min periods in buffer containing 50 mM Tris–HCl, pH 7.4, 120 mM NaCl, and 5 mM KCl. Next, they were incubated for 2 h in the same buffer also containing 0.025% bovine serum albumin (BSA), 1 μM fluoxetine, and 50 pM ^{125}I-RTI-121. Nonspecific binding was determined in the presence of the uptake inhibitor nomifensine (100 μM). Slides were then washed four times for 15 min in ice-cold buffer, once for 10 s in ice-cold water and air dried.

Striatal α4β2* nAChR levels were determined using ^{125}I-epibatidine (specific activity, 2200 Ci/mmol; PerkinElmer Life and Analytical Sciences, Waltham, MA, USA) in the presence of 10^{-7} μM of the α6β2* nAChR blocker α-conotoxinMII (α-CtxMII), as described (Quik et al., 2003). Briefly, the thawed sections were first pre-incubated for 15 min in binding buffer containing 50 mM Tris, pH 7.0, 120 mM NaCl, 5 mM KCl, 2.5 mM $CaCl_2$, and 1.0 mM $MgCl_2$ and α-CtxMII. This was followed by 40-min incubation in buffer also containing 0.03 nM ^{125}I-epibatidine with α-CtxMII. Nicotine (100 μM) was used to determine nonspecific binding. To terminate binding, the slides were washed twice for 5 min in ice-cold buffer and once for 10 s in ice-cold deionized water and air dried.

Striatal α6β2* nAChRs binding levels were measured using ^{125}I-α-CtxMII binding (^{125}I-α-CtxMII; specific activity, 2200 Ci/mmol) as previously described (Quik et al., 2003). The thawed sections were first pre-incubated for 15 min in binding buffer containing 144 mM NaCl, 1.5 mM KCl, 2 mM $CaCl_2$, 1 mM $MgSO_4$, 20 mM HEPES, 1 mM PMSF (phenylmethylsulfonyl fluoride) and 0.1% BSA, pH 7.5. Following pre-incubation, the slides were incubated for 1 h in binding buffer which also contained 0.5% BSA, 5 mM EDTA, 5 mM EGTA, 10 μg/ml each of aprotinin, leupeptin and pepstatin A, and 0.5 nM ^{125}I-α-CtxMII. Nicotine (100 μM) was used to determine nonspecific binding. The binding assay was terminated

by washing the slides for 10 min at 22 °C in binding buffer, 10 min in ice-cold binding buffer, twice for 10 min in ice-cold 0.1× binding buffer, and twice for 10 s in ice-cold deionized water.

After air drying, slides were exposed to Kodak MR Film (Easterman Kodak Co., Rochester, NY, USA) as needed along with ^{125}I-microscale standards (American Radiolabeled chemicals, Inc., Saint Louis, MO, USA).

Data analyses

For quantitation of the autoradiograms, optical density measurements were assessed using the Image-Quant system (GE Healthcare, Little Chalfont, Buckinghamshire, UK). These values were converted to fmol/mg tissue using standard curves generated from ^{125}I-standards. The optical density readings of the samples fell within the linear range of the standards. Data analyses were done with GraphPad Prism® (GraphPad Software, Inc., San Diego, CA, USA) using an analysis of variance (ANOVA) followed by the appropriate post hoc test. A level of 0.05 was considered significant.

RESULTS

Nicotine reduces L-dopa-induced AIMs in WT but not α6L9S mice

The results in Fig. 2 show the effect of nicotine on L-dopa-induced AIMs in WT and α6L9S mice over a 10-wk period. L-Dopa-induced AIMs were similar in the WT and α6L9S mice at the start of the nicotine treatment regimen with values of 26.1 ± 4.10 (n = 21) for WT and 21.7 ± 2.15 (n = 31) for α6L9S. The variability in AIMs was similar to that observed in our previous studies; the basis for this variability is not clear but does not appear to relate to the size of the lesion (Huang et al., 2011a; Quik et al., 2012, 2013b). Nicotine treatment led to a gradual decrease in total AIM scores in WT mice, which was significant at wk 8 and 10. By contrast, nicotine treatment had no effect on AIM scores in α6L9S mice. Since our previous studies demonstrated differential effects of nicotine in mice with low and higher AIM scores, mice were subdivided into two such groups (Huang et al., 2011a; Quik et al., 2012, 2013b). The data in the lower panels of Fig. 2 show that the results were comparable to those in the all mice group.

Fig. 3 depicts effects on the various L-dopa-induced AIM components, that is, oral, axial and forelimb AIMs in all mice, as well as in mice with low and higher AIM scores. The different AIM subtypes were similarly expressed in saccharin-treated WT and α6L9S mice. Nicotine treatment reduced AIMs in WT mice mainly via a decrease in oral AIMs, with a lesser effect on forelimb AIMs. Significant reductions ($p < 0.001$) were observed in oral AIMs in the all mice group (Fig. 3 top panel), as well as in mice with low ($p < 0.01$) and higher ($p < 0.01$) AIM scores (Fig. 3 lower panels). The nicotine-mediated reduction ($p < 0.01$) in forelimb AIM was observed only in the higher AIMs group (Fig 3 bottom). There was no effect of nicotine treatment on any AIM subtype in the α6L9S mice in any group. No axial AIMs were observed in the current study, possibly because total AIMs were not that severe in these experiments.



Fig. 2. Weekly time course showing a decrease in L-dopa-induced AIM scores with nicotine treatment in WT but not α6L9S. L-Dopa-treated lesioned WT and α6L9S mice were treated with saccharin (Sac) or nicotine (Nic) as detailed in the timeline in Fig. 1. The data shown are for 10 wk of treatment, for all mice (top), mice expressing low AIMs (middle) and mice expressing high AIMs (bottom). Values are the mean ± SEM of 3–10 mice. Significance of difference from the WT saccharin-treated group, $^{*}p < 0.05$, $^{**}p < 0.01$, $^{***}p < 0.001$; from the α6L9S nicotine-treated group, $^{+}p < 0.05$, $^{++}p < 0.01$, $^{+++}p < 0.001$ using two-way ANOVA followed by a Bonferroni post hoc test.

Our previous studies demonstrated that AIMs peaked ~60 min after L-dopa administration with an overall duration of effect of ~2 h (Huang et al., 2011a; Quik et al., 2012, 2013b). A similar pattern of AIMs expression was observed for α6L9S mice (Fig. 4). Again, nicotine treatment significantly reduced AIMs expression in WT mice but not α6L9S mice.



Fig. 3. Nicotine treatment decreased various L-dopa-induced AIMs components in WT but not α6L9S mice. Saccharin and nicotine-treated WT and α6L9S mice treated were rated for axial, oral and forelimb AIMs, with total AIMs representing the sum of the three components. The values shown are at 8 wk of nicotine treatment for all mice (top panels), mice expressing low AIMs (middle panels) and mice expressing high AIMs (bottom panels). Values are the mean ± SEM of 3–10 mice. Significance of difference from the WT saccharin-treated group, $^{**}p < 0.01$, $^{***}p < 0.001$ using two-way ANOVA followed by a Bonferroni post hoc test.

Parkinsonism was measured using the forepaw placement or cylinder test. In vehicle-treated unilateral 6-OHDA-lesioned WT mice, a decline was observed in contralateral forepaw use (37.3 ± 2.2%, $n = 17$), with similar results in unilaterally lesioned α6L9S mice (36.9 ± 2.3%, $n = 25$).

The nAChR blocker mecamylamine decreases L-dopa-induced AIMs in both WT and α6L9S mice

Our earlier studies had shown that the nAChR blocker mecamylamine also reduced L-dopa-induced AIMs (Bordia et al., 2010). These findings led to the suggestion that nicotine decreases L-dopa-induced AIMs via a desensitizing block. The present experiments were done to determine if mecamylamine also attenuated L-dopa-induced AIMs in mice expressing hypersensitive α6β2* nAChRs. The saccharin-treated WT and α6L9S mouse groups were injected 10 min before L-dopa administration for 1 or 2 d with saline or 1 mg/kg mecamylamine. This dose was used as previous studies had shown that it effectively reduces locomotor activity in α6L9S mice (Drenan et al., 2008), and WT mice (Bhutada et al., 2010; Biala and Staniak, 2010). Mecamylamine injection significantly reduced total AIMs and the individual AIM components in both WT mice and α6L9S mice, with the most pronounced effects after 2 d of treatment (Fig. 5). The observation that the nAChR blocker mecamylamine reduced AIMs despite a lack of effect of nicotine suggests that nicotine may no longer be able to desensitize hypersensitive α6β2* nAChRs. Such an interpretation would suggest that the antidyskinetic effect of nicotine is mediated primarily via α6β2* nAChRs.

Nicotine treatment leads to an improvement in dopamine transporter levels in 6-OHDA lesioned WT and α6L9S mice

Striatal dopamine transporter levels were measured using ^{125}I-RTI-121 binding on the intact and lesioned side of WT and α6L9S mice treated with nicotine or saccharin (Fig. 6). Dopamine transporter levels were similar in saccharin-treated WT and α6L9S mice. Nicotine treatment alone did not alter dopamine transporter levels on the intact side of WT mice, as previously shown (Huang et al., 2011a; Quik et al., 2012, 2013b).



Fig. 4. Hourly time course shows that nicotine treatment decreased L-dopa-induced AIMs throughout the treatment period in WT but not α6L9S mice. The data shown are for total L-dopa-induced AIMS for all mice (top), mice expressing low AIMs (middle) and mice expressing high AIMs (bottom) at 8 wk of nicotine treatment. Values are the mean ± SEM of 3–10 mice. Significance of difference from the WT saccharin-treated group, $^{*}p < 0.05$, $^{**}p < 0.01$; from α6L9S nicotine-treated group, $^{+}p < 0.05$, $^{++}p < 0.01$, $^{+++}p < 0.001$ using two-way ANOVA followed by a Bonferroni post hoc test.

Nicotine administration also did not affect transporter levels in the intact striatum of α6L9S mice. Lesioning alone decreased striatal ^{125}I-RTI-121 binding by 30% in WT, consistent with previous findings (Quik et al., 2003). Lesioning resulted in a similar decline in α6L9S mice, indicating that genetic manipulation of the α6 subunit did not influence the extent of nigrostriatal damage. Interestingly, long-term nicotine treatment led to improved transporter levels in both WT and α6L9S mice comparable to those on the intact side. These findings suggest that nicotine may induce sprouting of nigrostriatal dopamine terminals, with a consequent restoration of dopamine transporter levels.

Low-dose nicotine is sufficient to regulate striatal α4β2* but not α6β2* nAChRs in α6L9S mice

To evaluate whether the low dose of nicotine used in the drinking water of α6L9S mice modulated nAChR expression, we measured α4β2* nAChRs (Fig. 7). These receptors are well known to up-regulate with long-term nicotine treatment in WT mice (Marks et al., 1992; Pauly et al., 1996; Lai et al., 2005). α4β2* nAChR levels were determined by measuring ^{125}I-epibatidine in the presence of α-CtxMII to block binding to α6β2* nAChRs. The results show that α4β2* nAChR levels were similar in WT and α6L9S mice. 6-OHDA lesioning did not affect α4β2* nAChR binding levels, most likely because the majority of α4β2* nAChR in the striatum (80–85%) are not located on the lesioned nigrostriatal dopamine terminals (Quik et al., 2003). As expected, long-term nicotine treatment increased α4β2* nAChRs in the intact and lesioned striatum of WT mice (Lai et al., 2004). Notably, there was also an increase in α4β2* nAChR binding levels in the α6L9S mice. These data indicate that the low dose of nicotine (20 μg/ml) used to treat the α6L9S mice leads to changes in striatal nAChR expression.

In addition, experiments were done to determine whether nicotine treatment affected α6β2* nAChRs. α6β2* nAChRs were decreased on the lesioned side in both WT and α6L9S mice (Fig. 8), as expected since these are expressed on dopamine terminals in the striatum (Quik et al., 2003). Nicotine treatment down-regulated α6β2* nAChRs on the intact side of WT, consistent with previous studies (Lai et al., 2005). Nicotine treatment did not affect α6β2* nAChRs in α6L9S mice. With respect to combined lesioning and nicotine treatment, α6β2* nAChR levels were similar on the intact and lesioned side in WT mice. This result again suggests that the molecular integrity of dopamine terminals is restored/enhanced with nicotine treatment, in agreement with the DAT results in Fig. 6. By contrast, α6β2* nAChR levels remained low in the α6L9S mice, although α4β2* nAChRs were upregulated under the same treatment.

DISCUSSION

The present study provides further evidence for a role for α6β2* nAChRs in L-dopa-induced AIMs using gain-of-function α6L9S mice, a unique model exhibiting enhanced α6* receptor responsiveness. Consistent with previous studies, the present findings show that long-term nicotine treatment decreased L-dopa-induced AIMs in WT mice (Huang et al., 2011a; Quik et al., 2012). By contrast, no such decline was observed in mice expressing hypersensitive α6β2* nAChRs. Despite the lack of effect of the agonist nicotine on L-dopa-induced AIMs in α6L9S mice, the nAChR antagonist mecamylamine reduced AIMs in α6L9S mice to a similar extent as in WT mice, with these latter results in line with previous work in rats (Bordia et al., 2010). Since nicotine-mediated effects on behavior have been postulated to occur through nAChR desensitization, these data suggest that nicotine failed to desensitize α6L9S nAChRs. The present findings provide support for the idea that



Fig. 5. The general nAChR antagonist mecamylamine reduces AIMs in both WT and α6L9S mice. WT and α6L9S mice were injected with saline (Sal) or 1 mg/kg mecamylamine (Mec) 30 min before L-dopa for 1 or 2 d. Data shown are for a single injection (top panel) or two d of mecamylamine treatment (bottom panels). The hourly time is shown in the right panels. Values are the mean ± SEM of five mice per group. Significance of difference from the corresponding saline-treated group, $^{*}p < 0.05$, $^{**}p < 0.01$, $^{***}p < 0.001$; from WT saline-treated mice, $^{\#}p < 0.05$, $^{\#\#}p < 0.01$, $^{\#\#\#}p < 0.01$; from α6L9S mecamylamine-treated mice, $^{++}p < 0.01$ using two-way ANOVA followed by a Bonferroni post hoc.



Fig. 6. Nicotine treatment leads to an improvement in the dopamine transporter in 6-OHDA lesioned WT and α6L9S mice. 6-OHDA lesioning led to a decline in the dopamine transporter. By contrast, this decrease on the lesioned side was no longer observed in either WT and α6L9S mice with nicotine treatment. Values are the mean ± SEM of 7–10 mice per group. Significance of difference from the intact side of WT saccharin-treated mice, $^{**}p < 0.01$, $^{***}p < 0.01$.

nAChR-mediated declines in LIDs occur via desensitization and that α6β2* nAChRs are involved.

α6L9S mice have proved very useful for delineating a role for α6* nAChRs in regulating dopaminergic function (Drenan et al., 2008, 2010; Engle et al., 2013; Wang et al., 2014). These mice express an α6* nAChR in which the Leu 9′ residue in the M2 domain of the α6 subunit is modified to a Ser (Drenan et al., 2008). This change results in an α6* nAChR that is ~20 more sensitive to acetylcholine. This enhanced sensitivity is associated with an increase in dopamine neuron excitability in dopaminergic brain regions including the striatum, olfactory tubercle and ventral tegmental area (Drenan et al., 2008, 2010; Wang et al., 2014). In addition, there was augmented ^{3}H-dopamine release from synaptosomes and increased evoked extracellular dopamine levels in slices from α6L9S compared to WT mice (Drenan et al., 2008, 2010; Wang et al., 2014). HPLC measurements also



Fig. 7. Low-dose nicotine is sufficient to up-regulate α4β2* nAChRs in α6L9S mice. α4β2* nAChR levels were determined using ^{125}I-epibatidine autoradiography in the presence of α-CtxMII. Values are the mean ± SEM of 7–10 mice per group. Significant main effect of nicotine treatment, $^{**}p < 0.01$.



Fig. 8. Effect of lesioning and nicotine treatment on α6β2* nAChRs in WT and α6L9S mice. α6β2* nAChR levels were determined using ^{125}I-α-CtxMII autoradiography. α6β2* nAChRs were decreased on the lesioned side, as expected since these are primarily expressed on dopamine terminals in the striatum. Nicotine treatment down-regulated α6β2* nAChRs on the intact side of WT. However, α6β2* nAChR levels were similar on the intact and lesioned side in WT mice, in agreement with the DAT levels in Fig. 6. Nicotine treatment did not affect α6β2* nAChRs in α6L9S mice. Values are the mean ± SEM of 7–10 mice per group. Significance of difference from the intact side, $^{*}p < 0.01$, $^{***}p < 0.01$, $^{\#}p < 0.001$; from intact side of WT saccharin-treated mice.

demonstrated elevated levels of dopamine, 3,4-dihydroxyphenylacetic acid, and homovanillic acid in dopaminergic areas from α6L9S mice compared to WT, while Western blotting showed an increase in tyrosine hydroxylase (Wang et al., 2014). This enhanced dopaminergic function, in turn, led to altered behavioral responses including increased walking, turning and rearing in α6L9S compared to WT mice that may be linked to changes in nigrostriatal function (Drenan et al., 2008, 2010). Heightened dopaminergic function in the mesolimbic system has also been suggested from studies showing that α6L9S mice are more sensitive to the rewarding effects of alcohol (Powers et al., 2013). Since LIDs are thought to arise because of enhanced dopaminergic tone, an increase in their expression might have been expected in α6L9S mice. However, the similarity in LIDs in WT and α6L9S mice suggests that compensatory mechanisms developed to curtail their intensity in α6L9S mice. This is not unexpected since LIDs are modulated by numerous neurotransmitters, including the serotonergic,

glutamatergic, opioid, noradrenergic and GABAergic systems (Huot et al., 2013).

Not only do α6L9S mice exhibit enhanced spontaneous motor activities and increased responsiveness to the rewarding effects of alcohol, but they are also much more sensitive to the effects of administered nicotine. For instance, low-dose nicotine (0.02–0.15 mg/kg ip) markedly increased locomotor activity in α6L9S mice, while these doses had no effect in WT mice (Drenan et al., 2008). This elevated motor responsiveness was blocked by mecamylamine, indicating the effect was nAChR-mediated. These enhanced nicotine-mediated behavioral changes correlated well with nicotine-mediated hyper-responsiveness at the cellular level.

Evidence for enhanced sensitivity to nicotine is also readily evident in the current study, with the α6L9S mice being much less tolerant to a nicotine administration regimen that presented no problems in WT mice. Typically, nicotine dosing to WT mice is started at 25 μg/ml with a gradual increase to 300 μg/ml with no detectable adverse effects (Sparks and Pauly, 1999; Lai et al., 2005; Huang et al., 2011a). However, when α6L9S mice were subjected to a similar nicotine treatment regimen, 25% mortality was observed at 100 μg/ml nicotine. After several dose reductions, only a dose of 10 μg/ml was not associated with mortality.

Our previous results had shown that nicotine treatment reduced L-dopa-induced AIMs (Bordia et al., 2010; Huang et al., 2011b) and that mecamylamine administration also decreased their occurrence (Bordia et al., 2010) (Table 1). This somewhat unexpected observation that both a nAChR agonist and antagonist ameliorated AIMs led to the suggestion that nicotine exerted its effect via a desensitization blockade. Such an interpretation is consistent with other studies which indicate that nicotine modulates behaviors, such as cognition, addiction and depression, via a receptor activation followed by desensitization (Buccafusco et al., 2009; Mineur and Picciotto, 2010). The observation that mecamylamine still reduced L-dopa-induced AIMs in α6L9S mice would suggest that α6L9S receptors can still be blocked by an antagonist although they do not appear to be desensitized in response to nicotine exposure. Such an interpretation suggests that the antidyskinetic effect of nicotine is mediated via α6β2* nAChRs, at least in α6L9S mice.

A question that arises is whether the lack of effect of nicotine on L-dopa-induced AIMs in α6L9S mice may be due to the low dose of nicotine administered to the transgenic mice. The present data suggest this is unlikely. Our receptor studies show that α4β2* nAChRs are up-regulated in the striatum of WT mice, consistent with previous work (Marks et al., 1983; Pauly et al., 1996; Lai et al., 2005; Bordia et al., 2010). A significant receptor increase was also observed in α6L9S mice, attesting to the effectiveness of the low-dose nicotine in the brain. Second, studies involving measurement of the dopamine transporter show that elevated transporter levels were observed in the striatum of both lesioned WT and α6L9S mice following either dose of nicotine. This provides further evidence for efficacy of the lower nicotine dose in the α6L9S mice.

The present data show that long-term nicotine treatment increases striatal α4β2* nAChR levels (Marks et al., 1992; Lai et al., 2005; Srinivasan et al., 2014), while α6β2* nAChRs are decreased, as previously shown (Lai et al., 2005; Perry et al., 2007). Studies to understand the functional consequences of these opposing changes in nAChR levels with nicotine treatment show that nAChR-mediated dopamine release is decreased with chronic nicotine treatment (Quik et al., 2012; Bordia et al., 2013). This has been attributed to nicotine-induced α4β2* nAChR desensitization and the observed decline in α6β2* nAChRs (Marks et al., 1993; Bordia et al., 2013). In addition to the idea that chronic nicotine administration acts by decreasing dopamine release via striatal nAChR desensitization and down-regulation, other molecular changes may also be involved. It has been shown that nicotine treatment alters D1 and D2 receptor characteristics and modulates the function of striatal interneurons and medium spiny neurons (Garcia-Montes et al., 2012). In addition, nicotine administration affects GABA responsiveness in the substantia nigra and consequently nigrostriatal dopaminergic and striatal glutamatergic function (Xiao et al., 2009). Thus nicotine may act via multiple cellular and molecular mechanisms throughout the brain to diminish dopamine release and consequently reduce LIDs.

The receptor autoradiography data show that nigrostriatal damage results in a significant decline in striatal α6β2* nAChRs. By contrast, α4β2* nAChRs are not appreciably reduced in the current study probably due to the relatively small lesion. This apparent lack of effect on α4β2* nAChR relates the fact that only a small proportion of α4β2* nAChRs are present on nigrostriatal dopamine terminals with the majority present on other neurons in the striatum (Quik et al., 2003). However, dopamine release studies show that small declines in striatal α4β2* nAChR levels may be associated with significant losses in α4β2* nAChR-mediated function (Quik et al., 2003). Thus, drugs targeting α6β2* or α4β2* nAChRs may be of a similar value for therapeutic use.

The observation that nicotine dosing elevates dopamine transporter levels in the lesioned striatum was somewhat unexpected. This increased DAT is most likely on or within dopamine nerve terminals since DAT is only associated with dopaminergic neurons in the striatum (Seeman and Niznik, 1990; Miller et al., 1999). The enhanced DAT levels may be due to the relatively long-term nicotine treatment regimen used in the present study (6 months). This idea stems from studies showing that nAChR agonists and antagonists can modulate neuritic outgrowth in neuronal cells in culture (Chan and Quik, 1993; Zheng et al., 1994; Erskine and McCaig, 1995; Owen and Bird, 1995; Coronas et al., 2000). In addition, nicotine administration to rats increased fibroblast growth factor mRNA and protein, as well as nerve growth factor levels in rodent brain (Belluardo et al., 2000; Jonnala et al., 2002). Of more direct relevance to the current study, nicotine exposure increased dendritic arborization and soma size in mouse mesencephalic dopaminergic neurons in culture (Collo et al., 2013). Thus the nicotine-mediated increase in dopamine transporter levels in the striatum of WT and α6L9S mice may be

Table 1. Summary of the effect of nicotine and mecamylamine on L-dopa-induced AIMs in α6L9S and α6 (−/−) mice. The present results (Figs. 2–5) show that both nicotine and mecamylamine treatments decreased L-dopa-induced AIMs by ~50% in the α6 WT mice. By contrast, mecamylamine but not nicotine decreased AIMs in α6L9S mice. These data suggest that nAChR drugs reduce AIMs by an antagonist action. We hypothesize that the lack of effect of nicotine is due to its inability to desensitize hypersensitive α6L9S nAChRs, at least at the concentrations used in this study. Our previous work with α6 (−/−) mice had shown that baseline L-dopa-induced AIMs were reduced with no further decline with nicotine treatment (Quik et al., 2012). These combined observations suggest that α6* nAChRs play a major role in the expression of L-dopa-induced AIMs. Significance of difference from own WT saccharin-treated group: $^{**}p < 0.01$, $^{***}p < 0.01$

Treatment	Total L-dopa-induced AIMs (% saccharin WT)			
	α6 WT	α6L9S	α6 WT	α6 (-/-)
Saccharin	100 ± 10.1	100 ± 8.24	100 ± 14.7	41 ± 6.7***
Nicotine	58 ± 6.2**	104 ± 12.2	46 ± 7.3***	41 ± 8.5***
Mecamylamine	46 ± 3.7***	51 ± 12**	Not done	Not done

due to enhanced outgrowth of dopaminergic neurites that occurs when the system is compromised by lesioning.

In summary, the current studies using mice expressing gain-of function α6L9S nAChR further implicate α6β2* nAChRs in LIDs. In addition, the data suggest that α6β2* nAChR blockade may be a useful strategy for reducing LIDs. Since α6β2* nAChRs are expressed relatively selectively on dopaminergic neurons in the brain, the use of drugs targeting these receptors may yield beneficial results with a minimum of side effects.

CONFLICT OF INTEREST

There are no conflicts of interest.

Acknowledgments—This work was supported by a Purdue University Showalter Research Trust Award [to R.M.D] and grants from the National Institutes of Health [NS59910 and NS65851 to M.Q.; GM103801 and GM48677 to J.M.M.; and DA030396 to R.M.D.].

REFERENCES

Belluardo N, Mudo G, Blum M, Fuxe K (2000) Central nicotinic receptors, neurotrophic factors and neuroprotection. Behav Brain Res 113:21–34.

Bhutada PS, Mundhada YR, Bansod KU, Dixit PV, Umathe SN, Mundhada DR (2010) Inhibitory influence of mecamylamine on the development and the expression of ethanol-induced locomotor sensitization in mice. Pharmacol Biochem Behav 96:266–273.

Biala G, Staniak N (2010) Varenicline and mecamylamine attenuate locomotor sensitization and cross-sensitization induced by nicotine and morphine in mice. Pharmacol Biochem Behav 96:141–147.

Bordia T, Campos C, Huang L, Quik M (2008) Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease. J Pharmacol Exp Ther 327:239–247.

Bordia T, Campos C, McIntosh JM, Quik M (2010) Nicotinic receptor-mediated reduction in L-dopa-induced dyskinesias may occur via desensitization. J Pharmacol Exp Ther 333:929–938.

Bordia T, McIntosh JM, Quik M (2013) The nicotine-mediated decline in L-dopa-induced dyskinesias is associated with a decrease in striatal dopamine release. J Neurochem 125:291–302.

Buccafusco JJ, Beach JW, Terry AV (2009) Desensitization of nicotinic acetylcholine receptors as a strategy for drug development. J Pharmacol Exp Ther 328:364–370.

Chan J, Quik M (1993) A role for the nicotinic alpha-bungarotoxin receptor in neurite outgrowth in PC12 cells. Neuroscience 56:441–451.

Collo G, Bono F, Cavalleri L, Plebani L, Mitola S, Merlo Pich E, Millan MJ, Zoli M, Maskos U, Spano P, Missale C (2013) Nicotine-induced structural plasticity in mesencephalic dopaminergic neurons is mediated by dopamine D3 receptors and Akt-mTORC1 signaling. Mol Pharmacol 83:1176–1189.

Connolly BS, Lang AE (2014) Pharmacological treatment of Parkinson disease: a review. JAMA 311:1670–1683.

Coronas V, Durand M, Chabot JG, Jourdan F, Quirion R (2000) Acetylcholine induces neuritic outgrowth in rat primary olfactory bulb cultures. Neuroscience 98:213–219.

Di Paolo T, Gregoire L, Feuerbach D, Elbast W, Weiss M, Gomez-Mancilla B (2014) AQW051, a novel and selective nicotinic acetylcholine receptor alpha7 partial agonist, reduces L-Dopa-induced dyskinesias and extends the duration of L-Dopa effects in parkinsonian monkeys. Parkinsonism Relat Disord 20:1119–1123.

Drenan RM, Grady SR, Whiteaker P, McClure-Begley T, McKinney S, Miwa JM, Bupp S, Heintz N, McIntosh JM, Bencherif M, Marks MJ, Lester HA (2008) In vivo activation of midbrain dopamine neurons via sensitized, high-affinity alpha 6 nicotinic acetylcholine receptors. Neuron 60:123–136.

Drenan RM, Grady SR, Steele AD, McKinney S, Patzlaff NE, McIntosh JM, Marks MJ, Miwa JM, Lester HA (2010) Cholinergic modulation of locomotion and striatal dopamine release is mediated by alpha6alpha4* nicotinic acetylcholine receptors. J Neurosci 30:9877–9889.

Engle SE, Shih PY, McIntosh JM, Drenan RM (2013) Alpha4alpha6beta2* nAChR Activation on VTA DA neurons is sufficient to stimulate a depolarizing conductance and enhance surface AMPA receptor function. Mol Pharmacol 84:393–406.

Erskine L, McCaig CD (1995) Growth cone neurotransmitter receptor activation modulates electric field-guided nerve growth. Dev Biol 171:330–339.

Gaddnas H, Pietila K, Piepponen TP, Ahtee L (2001) Enhanced motor activity and brain dopamine turnover in mice during long-term nicotine administration in the drinking water. Pharmacol Biochem Behav 70:497–503.

Garcia-Montes JR, Boronat-Garcia A, Lopez-Colome AM, Bargas J, Guerra-Crespo M, Drucker-Colin R (2012) Is nicotine protective against Parkinson's disease? An experimental analysis. CNS Neurol Disord Drug Targets 11:897–906.

Huang L, Grady SR, Quik M (2011a) Nicotine reduces L-dopa-induced dyskinesias by acting at {beta}2 nicotinic receptors. J Pharmacol Exp Ther 338:932–941.

Huang LZ, Campos C, Ly J, Carroll FI, Quik M (2011b) Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in moderately lesioned parkinsonian rats. Neuropharmacology 60:861–868.

Huot P, Fox SH, Newman-Tancredi A, Brotchie JM (2011) Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to

reducing dyskinesia without exacerbating parkinsonism? J Pharmacol Exp Ther 339:2–8.
Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM (2013) The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. Pharmacol Rev 65:171–222.
Johnston TH, Huot P, Fox SH, Koprich JB, Szeliga KT, James JW, Graef JD, Letchworth SR, Jordan KG, Hill MP, Brotchie JM (2013) TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque. Neuropharmacology 73:337–347.
Jonnala RR, Terry Jr AV, Buccafusco JJ (2002) Nicotine increases the expression of high affinity nerve growth factor receptors in both in vitro and in vivo. Life Sci 70:1543–1554.
Lai A, Sum J, Fan H, McIntosh JM, Quik M (2004) Selective recovery of striatal 125I-alpha-conotoxinmii nicotinic receptors after nigrostriatal damage in monkeys. Neuroscience 127:399–408.
Lai A, Parameswaran N, Khwaja M, Whiteaker P, Lindstrom JM, Fan H, McIntosh JM, Grady SR, Quik M (2005) Long-term nicotine treatment decreases striatal alpha6* nicotinic acetylcholine receptor sites and function in mice. Mol Pharmacol 67: 1639–1647.
Lundblad M, Picconi B, Lindgren H, Cenci MA (2004) A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 16:110–123.
Lundblad M, Usiello A, Carta M, Hakansson K, Fisone G, Cenci MA (2005) Pharmacological validation of a mouse model of L-DOPA-induced dyskinesia. Exp Neurol 194:66–75.
Marks MJ, Burch JB, Collins AC (1983) Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. J Pharmacol Exp Ther 226:817–825.
Marks MJ, Pauly JR, Gross SD, Deneris ES, Hermans-Borgmeyer I, Heinemann SF, Collins AC (1992) Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment. J Neurosci 12:2765–2784.
Marks MJ, Grady SR, Collins AC (1993) Downregulation of nicotinic receptor function after chronic nicotine infusion. J Pharmacol Exp Ther 266:1268–1276.
Matta SG, Balfour DJ, Benowitz NL, Boyd RT, Buccafusco JJ, Caggiula AR, Craig CR, Collins AC, Damaj MI, Donny EC, Gardiner PS, Grady SR, Heberlein U, Leonard SS, Levin ED, Lukas RJ, Markou A, Marks MJ, McCallum SE, Parameswaran N, Perkins KA, Picciotto MR, Quik M, Rose JE, Rothenfluh A, Schafer WR, Stolerman IP, Tyndale RF, Wehner JM, Zirger JM (2007) Guidelines on nicotine dose selection for in vivo research. Psychopharmacology 190:269–319.
Millar NS, Gotti C (2009) Diversity of vertebrate nicotinic acetylcholine receptors. Neuropharmacology 56:237–246.
Miller GW, Gainetdinov RR, Levey AI, Caron MG (1999) Dopamine transporters and neuronal injury. Trends Pharmacol Sci 20:424–429.
Mineur YS, Picciotto MR (2010) Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends Pharmacol Sci 31:580–586.
Owen A, Bird M (1995) Acetylcholine as a regulator of neurite outgrowth and motility in cultured embryonic mouse spinal cord. NeuroReport 6:2269–2272.
Pauly JR, Marks MJ, Robinson SF, van de Kamp JL, Collins AC (1996) Chronic nicotine and mecamylamine treatment increase brain nicotinic receptor binding without changing alpha 4 or beta 2 mRNA levels. J Pharmacol Exp Ther 278:361–369.
Perry DC, Mao D, Gold AB, McIntosh JM, Pezzullo JC, Kellar KJ (2007) Chronic nicotine differentially regulates alpha6- and beta3-containing nicotinic cholinergic receptors in rat brain. J Pharmacol Exp Ther 322:306–315.
Picciotto MR, Addy NA, Mineur YS, Brunzell DH (2008) It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog Neurobiol 84:329–342.
Powers MS, Broderick HJ, Drenan RM, Chester JA (2013) Nicotinic acetylcholine receptors containing alpha6 subunits contribute to alcohol reward-related behaviours. Genes Brain Behav 12:543–553.
Quik M, Wonnacott S (2011) {alpha}6{beta}2* and {alpha}4{beta}2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease. Pharmacol Rev 63:938–966.
Quik M, Sum JD, Whiteaker P, McCallum SE, Marks MJ, Musachio J, McIntosh JM, Collins AC, Grady SR (2003) Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice. Mol Pharmacol 63:1169–1179.
Quik M, Cox H, Parameswaran N, O'Leary K, Langston JW, Di Monte D (2007) Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann Neurol 62:588–596.
Quik M, Park KM, Hrachova M, Mallela A, Huang LZ, McIntosh JM, Grady SR (2012) Role for alpha6 nicotinic receptors in L-dopa-induced dyskinesias in parkinsonian mice. Neuropharmacology 63:450–459.
Quik M, Campos C, Bordia T, Strachan JP, Zhang J, McIntosh JM, Letchworth S, Jordan K (2013a) Alpha4beta2 nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats. Neuropharmacology 71: 191–203.
Quik M, Campos C, Grady SR (2013b) Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice. Biochem Pharmacol 86:1153–1162.
Quik M, Zhang D, Perez XA, Bordia T (2014) Role for the nicotinic cholinergic system in movement disorders; therapeutic implications. Pharmacol Ther 144:50–59.
Seeman P, Niznik HB (1990) Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J 4:2737–2744.
Sparks JA, Pauly JR (1999) Effects of continuous oral nicotine administration on brain nicotinic receptors and responsiveness to nicotine in C57Bl/6 mice. Psychopharmacology 141:145–153.
Srinivasan R, Henderson BJ, Lester HA, Richards CI (2014) Pharmacological chaperoning of nAChRs: a therapeutic target for Parkinson's disease. Pharmacol Res 83:20–29.
Wang Y, Lee JW, Oh G, Grady SR, McIntosh JM, Brunzell DH, Cannon JR, Drenan RM (2014) Enhanced synthesis and release of dopamine in transgenic mice with gain-of-function alpha6* nAChRs. J Neurochem 129:315–327.
Won L, Ding Y, Singh P, Kang UJ (2014) Striatal cholinergic cell ablation attenuates L-DOPA induced dyskinesia in parkinsonian mice. J Neurosci 34:3090–3094.
Xiao C, Nashmi R, McKinney S, Cai H, McIntosh JM, Lester HA (2009) Chronic nicotine selectively enhances alpha4beta2* nicotinic acetylcholine receptors in the nigrostriatal dopamine pathway. J Neurosci 29:12428–12439.
Zhang D, Mallela A, Sohn D, Carroll FI, Bencherif M, Letchworth S, Quik M (2013) Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease. J Pharmacol Exp Ther 347:225–234.
Zhang D, Bordia T, McGregor M, McIntosh JM, Decker MW, Quik M (2014a) ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease. Mov Disord 29:508–517.
Zhang D, McGregor M, Decker MW, Quik M (2014b) The alpha7 nicotinic receptor agonist ABT-107 decreases L-dopa-induced dyskinesias in parkinsonian monkeys. J Pharmacol Exp Ther 351:25–32.
Zheng JQ, Felder M, Connor JA, Poo MM (1994) Turning of nerve growth cones induced by neurotransmitters. Nature 368:140–144.

(Accepted 19 March 2015)
(Available online 24 March 2015)